Concepts (53)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 3 | 2026 | 302 | 0.560 |
Why?
|
| Eclampsia | 1 | 2017 | 5 | 0.540 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 12 | 0.540 |
Why?
|
| Puerperal Disorders | 1 | 2017 | 14 | 0.540 |
Why?
|
| ADAMTS13 Protein | 1 | 2017 | 126 | 0.520 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2017 | 59 | 0.510 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2017 | 216 | 0.440 |
Why?
|
| Phenylthiohydantoin | 1 | 2026 | 8 | 0.250 |
Why?
|
| Benzamides | 1 | 2026 | 39 | 0.240 |
Why?
|
| Mutation | 2 | 2025 | 867 | 0.220 |
Why?
|
| Repressor Proteins | 1 | 2025 | 119 | 0.220 |
Why?
|
| Androgens | 1 | 2025 | 47 | 0.220 |
Why?
|
| Medicare Part D | 1 | 2024 | 5 | 0.220 |
Why?
|
| Prescription Drugs | 1 | 2024 | 15 | 0.220 |
Why?
|
| Nuclear Proteins | 1 | 2025 | 249 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 433 | 0.180 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 14 | 0.180 |
Why?
|
| Lymphoma | 1 | 2021 | 26 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 23 | 0.180 |
Why?
|
| Male | 6 | 2026 | 13921 | 0.160 |
Why?
|
| Aged | 4 | 2026 | 5598 | 0.150 |
Why?
|
| Humans | 8 | 2026 | 28851 | 0.150 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 686 | 0.140 |
Why?
|
| Lymphoma, Follicular | 1 | 2018 | 13 | 0.140 |
Why?
|
| Middle Aged | 4 | 2026 | 7414 | 0.140 |
Why?
|
| Female | 4 | 2018 | 15624 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2017 | 67 | 0.130 |
Why?
|
| Antibodies | 1 | 2018 | 125 | 0.130 |
Why?
|
| Plasma Exchange | 1 | 2017 | 104 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 336 | 0.120 |
Why?
|
| Registries | 1 | 2017 | 396 | 0.120 |
Why?
|
| Prognosis | 1 | 2017 | 811 | 0.110 |
Why?
|
| Adult | 2 | 2017 | 8024 | 0.110 |
Why?
|
| Neoplasms | 1 | 2024 | 874 | 0.110 |
Why?
|
| Oklahoma | 1 | 2017 | 1052 | 0.100 |
Why?
|
| Pregnancy | 1 | 2017 | 1254 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2017 | 2426 | 0.090 |
Why?
|
| Nitriles | 1 | 2026 | 38 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2026 | 32 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2026 | 118 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 1 | 2026 | 80 | 0.060 |
Why?
|
| Prostatectomy | 1 | 2026 | 90 | 0.060 |
Why?
|
| Microsatellite Instability | 1 | 2025 | 10 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2025 | 164 | 0.060 |
Why?
|
| Cost Savings | 1 | 2024 | 19 | 0.050 |
Why?
|
| Genomics | 1 | 2025 | 124 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2026 | 1280 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2025 | 472 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 415 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 84 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 285 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 347 | 0.040 |
Why?
|
| Animals | 1 | 2018 | 10684 | 0.010 |
Why?
|